Invention Grant
- Patent Title: Treatment of congenital adrenal hyperplasia
-
Application No.: US16227127Application Date: 2018-12-20
-
Publication No.: US10905690B2Publication Date: 2021-02-02
- Inventor: Dimitri E. Grigoriadis
- Applicant: Neurocrine Biosciences, Inc.
- Applicant Address: US CA San Diego
- Assignee: Neurocrine Biosciences, Inc.
- Current Assignee: Neurocrine Biosciences, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Fish & Richardson P.C.
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/4985 ; A61K31/427
Abstract:
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Public/Granted literature
- US20190231781A1 TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA Public/Granted day:2019-08-01
Information query
IPC分类:
